A federal lawyer heart two hours of oral arguments Friday from a lawyer representing two union health plans, accusing drug makers of fraud for coupons offered to consumers on brand name drugs. While the drug companies motioned to dismiss the two class actions, US District Judge Paul Oetken pressed the lawyer to explain how the coupons violated the law; according to reports, the coupons are accused to be “undisclosed kickbacks” and “commercial bribery” in violation of antitrust law intended to keep consumers on brand name drugs, often more expensive than their generic counterparts. According to the plaintiffs, the drug makers are utilizing coupons to preserve their market shares. According to reports, the Judge did not seem entirely convinced of the claims made.
Full Content: Thomson Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI